Ali J Marian

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2994913/publications.pdf

Version: 2024-02-01

207 papers	15,017 citations	20759 60 h-index	19136 118 g-index
221 all docs	221 docs citations	221 times ranked	15123 citing authors

#	Article	IF	Citations
1	COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovascular Research, 2020, 116, 1666-1687.	1.8	1,074
2	Hypertrophic Cardiomyopathy. Circulation Research, 2017, 121, 749-770.	2.0	790
3	Tissue Doppler Imaging Consistently Detects Myocardial Abnormalities in Patients With Hypertrophic Cardiomyopathy and Provides a Novel Means for an Early Diagnosis Before and Independently of Hypertrophy. Circulation, 2001, 104, 128-130.	1.6	563
4	Identification of a Genetic Locus for Familial Atrial Fibrillation. New England Journal of Medicine, 1997, 336, 905-911.	13.9	533
5	Suppression of canonical Wnt/Â-catenin signaling by nuclear plakoglobin recapitulates phenotype of arrhythmogenic right ventricular cardiomyopathy. Journal of Clinical Investigation, 2006, 116, 2012-2021.	3.9	519
6	Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2020, 396, 759-769.	6.3	481
7	Mutations in Smooth Muscle Alpha-Actin (ACTA2) Cause Coronary Artery Disease, Stroke, and Moyamoya Disease, Along with Thoracic Aortic Disease. American Journal of Human Genetics, 2009, 84, 617-627.	2.6	466
8	The Molecular Genetic Basis for Hypertrophic Cardiomyopathy. Journal of Molecular and Cellular Cardiology, 2001, 33, 655-670.	0.9	394
9	Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death. Lancet, The, 1993, 342, 1085-1086.	6.3	385
10	Angiotensin II Blockade Reverses Myocardial Fibrosis in a Transgenic Mouse Model of Human Hypertrophic Cardiomyopathy. Circulation, 2001, 103, 789-791.	1.6	352
11	Simvastatin Induces Regression of Cardiac Hypertrophy and Fibrosis and Improves Cardiac Function in a Transgenic Rabbit Model of Human Hypertrophic Cardiomyopathy. Circulation, 2001, 104, 317-324.	1.6	323
12	A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease.. Journal of Clinical Investigation, 1995, 96, 3005-3008.	3.9	303
13	Tissue Doppler Imaging Predicts the Development of Hypertrophic Cardiomyopathy in Subjects With Subclinical Disease. Circulation, 2003, 108, 395-398.	1.6	249
14	MYH11 mutations result in a distinct vascular pathology driven by insulin-like growth factor 1 and angiotensin II. Human Molecular Genetics, 2007, 16, 2453-2462.	1.4	243
15	The Hippo Pathway Is Activated and Is a Causal Mechanism for Adipogenesis in Arrhythmogenic Cardiomyopathy. Circulation Research, 2014, 114, 454-468.	2.0	227
16	Aldosterone, Through Novel Signaling Proteins, Is a Fundamental Molecular Bridge Between the Genetic Defect and the Cardiac Phenotype of Hypertrophic Cardiomyopathy. Circulation, 2004, 109, 1284-1291.	1.6	221
17	Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure, and metabolism. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 2748-2753.	3.3	218
18	Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy. Lancet, The, 2000, 355, 58-60.	6.3	217

#	Article	IF	Citations
19	Tissue Doppler Imaging Consistently Detects Myocardial Contraction and Relaxation Abnormalities, Irrespective of Cardiac Hypertrophy, in a Transgenic Rabbit Model of Human Hypertrophic Cardiomyopathy. Circulation, 2000, 102, 1346-1350.	1.6	176
20	Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2020, 75, 2649-2660.	1.2	176
21	Angiotensin-I Converting Enzyme Genotypes and Left Ventricular Hypertrophy in Patients With Hypertrophic Cardiomyopathy. Circulation, 1995, 92, 1808-1812.	1.6	176
22	A transgenic rabbit model for human hypertrophic cardiomyopathy. Journal of Clinical Investigation, 1999, 104, 1683-1692.	3.9	171
23	Myozenin 2 Is a Novel Gene for Human Hypertrophic Cardiomyopathy. Circulation Research, 2007, 100, 766-768.	2.0	168
24	Recent Advances in the Molecular Genetics of Hypertrophic Cardiomyopathy. Circulation, 1995, 92, 1336-1347.	1.6	162
25	Early diagnosis of acute myocardial infarction based on assay for subforms of creatine kinase-MB.. Circulation, 1990, 82, 759-764.	1.6	159
26	A Common PCSK9Haplotype, Encompassing the E670G Coding Single Nucleotide Polymorphism, Is a Novel Genetic Marker for Plasma Low-Density Lipoprotein Cholesterol Levels and Severity of Coronary Atherosclerosis. Journal of the American College of Cardiology, 2005, 45, 1611-1619.	1.2	146
27	Nuclear Plakoglobin Is Essential for Differentiation of Cardiac Progenitor Cells to Adipocytes in Arrhythmogenic Right Ventricular Cardiomyopathy. Circulation Research, 2011, 109, 1342-1353.	2.0	145
28	Prevention of Cardiac Hypertrophy by Atorvastatin in a Transgenic Rabbit Model of Human Hypertrophic Cardiomyopathy. Circulation Research, 2005, 97, 285-292.	2.0	143
29	Transgenic Mouse Model of Ventricular Preexcitation and Atrioventricular Reentrant Tachycardia Induced by an AMP-Activated Protein Kinase Loss-of-Function Mutation Responsible for Wolff-Parkinson-White Syndrome. Circulation, 2005, 111, 21-29.	1.6	139
30	Genetic Fate Mapping Identifies Second Heart Field Progenitor Cells As a Source of Adipocytes in Arrhythmogenic Right Ventricular Cardiomyopathy. Circulation Research, 2009, 104, 1076-1084.	2.0	135
31	A Variant of p22 ^{phox} , Involved in Generation of Reactive Oxygen Species in the Vessel Wall, Is Associated With Progression of Coronary Atherosclerosis. Circulation Research, 2000, 86, 391-395.	2.0	134
32	Expression profiling of cardiac genes in human hypertrophic cardiomyopathy: insight into the pathogenesis of phenotypes. Journal of the American College of Cardiology, 2001, 38, 1175-1180.	1.2	131
33	Framework for development of physician competencies in genomic medicine: report of the Competencies Working Group of the Inter-Society Coordinating Committee for Physician Education in Genomics. Genetics in Medicine, 2014, 16, 804-809.	1.1	123
34	Localization of a Gene Responsible for Familial Dilated Cardiomyopathy to Chromosome 1q32. Circulation, 1995, 92, 3387-3389.	1.6	123
35	Molecular genetic studies of complex phenotypes. Translational Research, 2012, 159, 64-79.	2.2	121
36	Plasma Homocyst(e)ine Concentration, But Not MTHFR Genotype, Is Associated With Variation in Carotid Plaque Area. Stroke, 1999, 30, 969-973.	1.0	118

#	Article	IF	Citations
37	Human Molecular Genetic and Functional Studies Identify TRIM63 , Encoding Muscle RING Finger Protein 1, as a Novel Gene for Human Hypertrophic Cardiomyopathy. Circulation Research, 2012, 111, 907-919.	2.0	117
38	Simvastatin Induces Regression of Cardiac Hypertrophy and Fibrosis and Improves Cardiac Function in a Transgenic Rabbit Model of Human Hypertrophic Cardiomyopathy. Circulation, 2001, 104, 317-324.	1.6	114
39	Sudden cardiac death in hypertrophic cardiomyopathy. European Heart Journal, 1995, 16, 368-376.	1.0	113
40	Dominant-negative effect of a mutant cardiac troponin T on cardiac structure and function in transgenic mice.. Journal of Clinical Investigation, 1998, 102, 1498-1505.	3.9	108
41	Resolution of Established Cardiac Hypertrophy and Fibrosis and Prevention of Systolic Dysfunction in a Transgenic Rabbit Model of Human Cardiomyopathy Through Thiol-Sensitive Mechanisms. Circulation, 2009, 119, 1398-1407.	1.6	106
42	Antifibrotic Effects of Antioxidant N-Acetylcysteine in a Mouse Model of Human Hypertrophic Cardiomyopathy Mutation. Journal of the American College of Cardiology, 2006, 47, 827-834.	1.2	105
43	Novel Polymorphisms in Promoter Region of ATP Binding Cassette Transporter Gene and Plasma Lipids, Severity, Progression, and Regression of Coronary Atherosclerosis and Response to Therapy. Circulation Research, 2001, 88, 969-973.	2.0	104
44	Hypertrophic cardiomyopathy: from genetics to treatment. European Journal of Clinical Investigation, 2010, 40, 360-369.	1.7	99
45	Molecular Genetic Basis of Hypertrophic Cardiomyopathy:.. Journal of Cardiovascular Electrophysiology, 1998, 9, 88-99.	0.8	97
46	Strategic Approaches to Unraveling Genetic Causes of Cardiovascular Diseases. Circulation Research, 2011, 108, 1252-1269.	2.0	95
47	DNA Damage Response/TP53 Pathway Is Activated and Contributes to the Pathogenesis of Dilated Cardiomyopathy Associated With LMNA (Lamin A/C) Mutations. Circulation Research, 2019, 124, 856-873.	2.0	95
48	Apolipoprotein E genotypes and response of plasma lipids and progressionâ€“regression of coronary atherosclerosis to lipid-lowering drug therapy. Journal of the American College of Cardiology, 2000, 36, 1572-1578.	1.2	91
49	Molecular Genetic Basis of Hypertrophic Cardiomyopathy. Circulation Research, 2021, 128, 1533-1553.	2.0	88
50	Cardiac Fibro-Adipocyte Progenitors Express Desmosome Proteins and Preferentially Differentiate to Adipocytes Upon Deletion of the Desmoplakin Gene. Circulation Research, 2016, 119, 41-54.	2.0	85
51	Expression of a Mutant (Arg ⁹² Gln) Human Cardiac Troponin T, Known to Cause Hypertrophic Cardiomyopathy, Impairs Adult Cardiac Myocyte Contractility. Circulation Research, 1997, 81, 76-85.	2.0	84
52	A common mutation in methylenetetrahydrofolate reductase gene is not a major risk of coronary artery disease or myocardial infarction. Atherosclerosis, 1997, 128, 107-112.	0.4	83
53	Metabolomic distinction and insights into the pathogenesis of human primary dilated cardiomyopathy. European Journal of Clinical Investigation, 2011, 41, 527-538.	1.7	79
54	Variants of Trophic Factors and Expression of Cardiac Hypertrophy in Patients with Hypertrophic Cardiomyopathy. Journal of Molecular and Cellular Cardiology, 2000, 32, 2369-2377.	0.9	78

#	Article	IF	Citations
55	Genetic determinants of cardiac hypertrophy. Current Opinion in Cardiology, 2008, 23, 199-205.	0.8	78
56	Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin. Journal of the American College of Cardiology, 2000, 35, 89-95.	1.2	77
57	Genome-wide mapping of modifier chromosomal loci for human hypertrophic cardiomyopathy. Human Molecular Genetics, 2007, 16, 2463-2471.	1.4	74
58	Detection of a new mutation in the beta-myosin heavy chain gene in an individual with hypertrophic cardiomyopathy.. Journal of Clinical Investigation, 1992, 90, 2156-2165.	3.9	73
59	Genomic Reorganization of Lamin-Associated Domains in Cardiac Myocytes Is Associated With Differential Gene Expression and DNA Methylation in Human Dilated Cardiomyopathy. Circulation Research, 2019, 124, 1198-1213.	2.0	72
60	Platelet Glycoprotein IIIaPlAPolymorphism and Myocardial Infarction. New England Journal of Medicine, 1996, 335, 1071-1074.	13.9	66
61	Expression of a Mutation Causing Hypertrophic Cardiomyopathy Disrupts Sarcomere Assembly in Adult Feline Cardiac Myocytes. Circulation Research, 1995, 77, 98-106.	2.0	62
62	A prospective study of paraoxonase gene Q/R192 polymorphism and severity, progression and regression of coronary atherosclerosis, plasma lipid levels, clinical events and response to fluvastatin. Atherosclerosis, 2001, 154, 633-640.	0.4	55
63	Elements of â€˜missing heritabilityâ€™. Current Opinion in Cardiology, 2012, 27, 197-201.	0.8	55
64	Current state of vaccine development and targeted therapies for COVID-19: impact of basic science discoveries. Cardiovascular Pathology, 2021, 50, 107278.	0.7	55
65	Differential interactions of thin filament proteins in two cardiac troponin T mouse models of hypertrophic and dilated cardiomyopathies. Cardiovascular Research, 2008, 79, 109-117.	1.8	54
66	Suppression of Activated FOXO Transcription Factors in the Heart Prolongs Survival in a Mouse Model of Laminopathies. Circulation Research, 2018, 122, 678-692.	2.0	54
67	Regulatable atrial natriuretic peptide gene therapy for hypertension. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 13789-13794.	3.3	52
68	Enhanced Transmural Fiber Rotation and Connexin 43 Heterogeneity Are Associated With an Increased Upper Limit of Vulnerability in a Transgenic Rabbit Model of Human Hypertrophic Cardiomyopathy. Circulation Research, 2007, 101, 1049-1057.	2.0	50
69	Evolution of expression of cardiac phenotypes over a 4-year period in the $beta;-myosin heavy chain-Q403 transgenic rabbit model of human hypertrophic cardiomyopathy. Journal of Molecular and Cellular Cardiology, 2004, 36, 663-673.	0.9	48
70	Molecular Genetic and Functional Characterization Implicate Muscle-Restricted Coiled-Coil Gene () Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Genetics, 2011, 4, 349-358.	5.1	48
71	A Potential Oligogenic Etiology of Hypertrophic Cardiomyopathy. Circulation Research, 2017, 120, 1084-1090.	2.0	47
72	Expression of a missense mutation in the messenger RNA for beta-myosin heavy chain in myocardial tissue in hypertrophic cardiomyopathy.. Journal of Clinical Investigation, 1992, 90, 271-277.	3.9	47

#	Article	IF	Citations
73	Exercise restores dysregulated gene expression in a mouse model of arrhythmogenic cardiomyopathy. Cardiovascular Research, 2020, 116, 1199-1213.	1.8	44
74	Candidate genetic analysis of plasma high-density lipoprotein-cholesterol and severity of coronary atherosclerosis. BMC Medical Genetics, 2009, 10, 111.	2.1	43
75	Molecular Genetics and Pathogenesis of Arrhythmogenic Right Ventricular Cardiomyopathy: A Disease of Cardiac Stem Cells. Pediatric Cardiology, 2011, 32, 360-365.	0.6	43
76	Genetics and Genomics of Single-Gene Cardiovascular Diseases. Journal of the American College of Cardiology, 2016, 68, 2831-2849.	1.2	43
77	Knockdown of Plakophilin 2 Downregulates miR-184 Through CpG Hypermethylation and Suppression of the E2F1 Pathway and Leads to Enhanced Adipogenesis In Vitro. Circulation Research, 2016, 119, 731-750.	2.0	43
78	Effects of SREBF-1a and SCAP polymorphisms on plasma levels of lipids, severity, progression and regression of coronary atherosclerosis and response to therapy with fluvastatin. Journal of Molecular Medicine, 2002, 80, 737-744.	1.7	42
79	Hypertrophy Regression With N-Acetylcysteine in Hypertrophic Cardiomyopathy (HALT-HCM). Circulation Research, 2018, 122, 1109-1118.	2.0	42
80	Widespread myocardial dysfunction in COVID-19 patients detected by myocardial strain imaging using 2-D speckle-tracking echocardiography. Acta Pharmacologica Sinica, 2021, 42, 1567-1574.	2.8	42
81	BET bromodomain inhibition attenuates cardiac phenotype in myocyte-specific lamin A/Câ€“deficient mice. Journal of Clinical Investigation, 2020, 130, 4740-4758.	3.9	42
82	Pathogenesis of hypertrophic cardiomyopathy caused by myozenin 2 mutations is independent of calcineurin activity. Cardiovascular Research, 2013, 97, 44-54.	1.8	39
83	Natureâ€™s Genetic Gradients and the Clinical Phenotype. Circulation: Cardiovascular Genetics, 2009, 2, 537-539.	5.1	37
84	Genomics in Cardiovascular Disease. Journal of the American College of Cardiology, 2013, 61, 2029-2037.	1.2	37
85	Contemporary treatment of hypertrophic cardiomyopathy. Texas Heart Institute Journal, 2009, 36, 194-204.	0.1	37
86	Atorvastatin and cardiac hypertrophy and function in hypertrophic cardiomyopathy: a pilot study. European Journal of Clinical Investigation, 2010, 40, 976-983.	1.7	36
87	Challenges in Medical Applications of Whole Exome/Genome Sequencing Discoveries. Trends in Cardiovascular Medicine, 2012, 22, 219-223.	2.3	36
88	Lipoprotein lipase gene mutations, plasma lipid levels, progression/regression of coronary atherosclerosis, response to therapy, and future clinical events. Atherosclerosis, 1999, 144, 435-442.	0.4	35
89	Human polymorphism of P-selectin glycoprotein ligand 1 attributable to variable numbers of tandem decameric repeats in the mucinlike region. Blood, 2001, 97, 3306-3307.	0.6	35
90	Experimental Therapies in Hypertrophic Cardiomyopathy. Journal of Cardiovascular Translational Research, 2009, 2, 483-492.	1.1	35

#	Article	IF	Citations
91	A prospective study of genetic markers of susceptibility to infection and inflammation, and the severity, progression, and regression of coronary atherosclerosis and its response to therapy. Journal of Molecular Medicine, 2000, 78, 562-568.	1.7	34
92	The 9p21 susceptibility locus for coronary artery disease and the severity of coronary atherosclerosis. BMC Cardiovascular Disorders, 2009, 9, 3.	0.7	34
93	Sudden cardiac death in patients with hypertrophic cardiomyopathy: From bench to bedside with an emphasis on genetic markers. Clinical Cardiology, 1995, 18, 189-198.	0.7	33
94	FAT10 protects cardiac myocytes against apoptosis. Journal of Molecular and Cellular Cardiology, 2013, 59, 1-10.	0.9	31
95	Arrhythmogenic right ventricular cardiomyopathy is a disease of cardiac stem cells. Current Opinion in Cardiology, 2010, 25, 222-228.	0.8	30
96	Causality in Genetics. Circulation Research, 2014, 114, e18-21.	2.0	30
97	Recent Developments in Cardiovascular Stem Cells. Circulation Research, 2014, 115, e71-8.	2.0	29
98	On Genetics, Inflammation, and Abdominal Aortic Aneurysm. Circulation, 2001, 103, 2222-2224.	1.6	28
99	On Mice, Rabbits, and Human Heart Failure. Circulation, 2005, 111, 2276-2279.	1.6	28
100	Genetic basis and molecular biology of cardiac arrhythmias in cardiomyopathies. Cardiovascular Research, 2020, 116, 1600-1619.	1.8	28
101	MOLECULAR GENETICS OF HYPERTROPHIC CARDIOMYOPATHY. Annual Review of Medicine, 1995, 46, 213-222.	5.0	27
102	On predictors of sudden cardiac death in hypertrophic cardiomyopathy**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.. Journal of the American College of Cardiology, 2003, 41, 994-996.	1.2	27
103	The Enigma of Genetics Etiology of Atherosclerosis in the Post-GWAS Era. Current Atherosclerosis Reports, 2012, 14, 295-299.	2.0	27
104	Association of Angiotensin I-Converting Enzyme Gene Polymorphism With Myocardial Ischemia and Patency of Infarct-Related Artery in Patients With Acute Myocardial Infarction. Journal of the American College of Cardiology, 1997, 29, 1468-1473.	1.2	26
105	Distinct Cellular Basis for Early Cardiac Arrhythmias, the Cardinal Manifestation of Arrhythmogenic Cardiomyopathy, and the Skin Phenotype of Cardiocutaneous Syndromes. Circulation Research, 2017, 121, 1346-1359.	2.0	26
106	Decreased Left Ventricular Ejection Fraction in Transgenic Mice Expressing Mutant Cardiac Troponin T-Q92, Responsible for Human Hypertrophic Cardiomyopathy. Journal of Molecular and Cellular Cardiology, 2000, 32, 365-374.	0.9	25
107	Induction and reversal of cardiac phenotype of human hypertrophic cardiomyopathy mutation cardiac troponin T-Q92 in switch onâ€“switch off bigenic mice. Journal of the American College of Cardiology, 2004, 44, 2221-2230.	1.2	25
108	Haploinsufficiency ofTmem43in cardiac myocytes activates the DNA damage response pathway leading to a late-onset senescence-associated pro-fibrotic cardiomyopathy. Cardiovascular Research, 2021, 117, 2377-2394.	1.8	25

#	Article	IF	Citations
109	Biomarkers of cardiac disease. Expert Review of Molecular Diagnostics, 2004, 4, 805-820.	1.5	24
110	Î²-adrenergic receptors signaling and heart failure in mice, rabbits and humansâ˜†. Journal of Molecular and Cellular Cardiology, 2006, 41, 11-13.	0.9	23
111	Mitochondrial Genetics and Human Systemic Hypertension. Circulation Research, 2011, 108, 784-786.	2.0	23
112	Arrhythmogenic Cardiomyopathy in a Patient With a Rare Lossâ€ofâ€Function KCNQ1 Mutation. Journal of the American Heart Association, 2015, 4, e001526.	1.6	23
113	RNA sequencing-based transcriptome profiling of cardiac tissue implicates novel putative disease mechanisms in FLNC-associated arrhythmogenic cardiomyopathy. International Journal of Cardiology, 2020, 302, 124-130.	0.8	23
114	Clinical Interpretation and Management of Genetic Variants. JACC Basic To Translational Science, 2020, 5, 1029-1042.	1.9	23
115	Single-Cell RNA Sequencing Uncovers Paracrine Functions of the Epicardial-Derived Cells in Arrhythmogenic Cardiomyopathy. Circulation, 2021, 143, 2169-2187.	1.6	22
116	Inadvertent administration of rtPA to a patient with type 1 aortic dissection and subsequent cardiac tamponade. American Journal of Emergency Medicine, 1993, 11, 613-615.	0.7	21
117	To Screen or Not Is Not the Questionâ€" It Is When and How to Screen. Circulation, 2003, 107, 2171-2174.	1.6	21
118	Modeling Human Disease Phenotype in Model Organisms. Circulation Research, 2011, 109, 356-359.	2.0	21
119	Sequencing Your Genome: What Does it Mean?. Methodist DeBakey Cardiovascular Journal, 2021, 10, 3.	0.5	21
120	Release kinetics of circulating cardiac myosin binding protein-C following cardiac injury. American Journal of Physiology - Heart and Circulatory Physiology, 2014, 306, H547-H556.	1.5	20
121	The EP300/TP53 pathway, a suppressor of the Hippo and canonical WNT pathways, is activated in human hearts with arrhythmogenic cardiomyopathy in the absence of overt heart failure. Cardiovascular Research, 2022, 118, 1466-1478.	1.8	20
122	The Discovery of the ACE2 Gene. Circulation Research, 2013, 112, 1307-1309.	2.0	19
123	Challenges in the Diagnosis of Anderson-Fabry Disease. Journal of the American College of Cardiology, 2016, 68, 1051-1053.	1.2	19
124	Knock Down of Plakophillin 2 Dysregulates Adhesion Pathway through Upregulation of miR200b and Alters the Mechanical Properties in Cardiac Cells. Cells, 2019, 8, 1639.	1.8	18
125	Medical DNA sequencing. Current Opinion in Cardiology, 2011, 26, 175-180.	0.8	17
126	Surprises of the Genome and â€œPersonalizedâ€•MedicineâžâžEditorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. Journal of the American College of Cardiology, 2008, 51, 456-458.	1.2	16

#	Article	IF	Citations
127	Apolipoprotein Îµ4 is not a genetic risk factor for coronary artery disease or restenosis after percutaneous transluminal coronary angioplasty. American Journal of Cardiology, 1995, 75, 1181-1183.	0.7	15
128	Noncoding RNAs in Cardiovascular Biology and Disease. Circulation Research, 2013, 113, e115-20.	2.0	15
129	Identifying Modifier Loci in Existing Genome Scan Data. Annals of Human Genetics, 2008, 72, 670-675.	0.3	13
130	PCSK9 as a Therapeutic Target in Atherosclerosis. Current Atherosclerosis Reports, 2010, 12, 151-154.	2.0	12
131	The Case of â€œMissing Causal Genesâ€•and the Practice of Medicine. Circulation Research, 2016, 119, 21-24.	2.0	12
132	FAT10 protects against ischemia-induced ventricular arrhythmia by decreasing Nedd4-2/Nav1.5 complex formation. Cell Death and Disease, 2021, 12, 25.	2.7	11
133	Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: Design and rationale of the SYNERGY Library. American Heart Journal, 2004, 148, 269-276.	1.2	10
134	A Calsequestrin Cis-Regulatory Motif Coupled to a Cardiac Troponin T Promoter Improves Cardiac Adeno-Associated Virus Serotype 9 Transduction Specificity. Human Gene Therapy, 2018, 29, 927-937.	1.4	10
135	A rare loss-of-function SCN5A variant is associated with lidocaine-induced ventricular fibrillation. Pharmacogenomics Journal, 2014, 14, 372-375.	0.9	9
136	Congenital Heart Disease. Circulation Research, 2017, 120, 895-897.	2.0	9
137	Efficacy of Nifekalant in Patients With Wolffâ€Parkinsonâ€White Syndrome and Atrial Fibrillation: Electrophysiological and Clinical Findings. Journal of the American Heart Association, 2019, 8, e012511.	1.6	9
138	Identification of Genes and Pathways Regulated by Lamin A in Heart. Journal of the American Heart Association, 2020, 9, e015690.	1.6	9
139	Effects of tamoxifen inducible MerCreMer on gene expression in cardiac myocytes in mice. , 2022, 2, .		9
140	Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome. Journal of Thrombosis and Thrombolysis, 2011, 31, 146-153.	1.0	8
141	Molecular, Cellular, and Functional Characterization of Myocardial Regions in Hypertrophic Cardiomyopathy. Circulation: Cardiovascular Imaging, 2012, 5, 419-422.	1.3	8
142	Identification of established arrhythmogenic right ventricular cardiomyopathy mutation in a patient with the contrasting phenotype of hypertrophic cardiomyopathy. BMC Medical Genetics, 2017, 18, 24.	2.1	8
143	Introduction to Cardiovascular Aging Compendium. Circulation Research, 2018, 123, 737-739.	2.0	8
144	Clinical Significance of Variants in the TTN Gene in a Large Cohort of Patients With Sporadic Dilated Cardiomyopathy. Frontiers in Cardiovascular Medicine, 2021, 8, 657689.	1.1	8

#	Article	IF	Citations
145	Genetic markers: genes Involved in atherosclerosis. European Journal of Cardiovascular Prevention and Rehabilitation, 1997, 4, 333-339.	1.5	7
146	On Koch's Postulates, Causality and Genetics of Cardiomyopathies. Journal of Molecular and Cellular Cardiology, 2002, 34, 971-974.	0.9	7
147	Determinants of plasma vitamin D levels in patients with acute coronary syndromes. European Journal of Clinical Investigation, 2011, 41, 1299-1309.	1.7	7
148	Non-syndromic cardiac progeria in a patient with the rare pathogenic p.Asp300Asn variant in the LMNA gene. BMC Medical Genetics, 2017, 18, 116.	2.1	7
149	The WNT/Î²-catenin pathway regulates expression of the genes involved in cell cycle progression and mitochondrial oxidative phosphorylation in the postmitotic cardiac myocytes. , 2022, 2, .		7
150	Copy Number Variants and the Genetic Enigma of Congenital Heart Disease. Circulation Research, 2014, 115, 821-823.	2.0	6
151	Recent Developments in Cardiovascular Genetics and Genomics. Circulation Research, 2014, 115, e11-7.	2.0	6
152	Genetic Causality in Complex Traits. Journal of the American College of Cardiology, 2016, 67, 417-419.	1.2	6
153	In Vivo Short-Term Expression of a Hypertrophic Cardiomyopathy Mutation in Adult Rabbit Myocardium: Myof ibrillar Incorporation without Early Disarray. Proceedings of the Association of American Physicians, 1999, 111, 45-56.	2.1	6
154	Molecular Approaches for Screening of Genetic Diseases. Chest, 1995, 108, 255-265.	0.4	5
155	Genetic markers: genes involved in human hypertension. European Journal of Cardiovascular Prevention and Rehabilitation, 1997, 4, 341-345.	1.5	5
156	Cytochrome P-450 polymorphisms and response to clopidogrel. Current Atherosclerosis Reports, 2009, 11, 157-160.	2.0	5
157	Circulation Researchand Human Genetic Studies. Circulation Research, 2010, 107, 6-8.	2.0	5
158	Genome-Wide Association Studies Complemented with Mechanistic Biological Studies Identify Sortilin 1 as a Novel Regulator of Cholesterol Trafficking. Current Atherosclerosis Reports, 2011, 13, 190-192.	2.0	5
159	On the diagnostic utility of junction plakoglobin in arrhythmogenic right ventricular cardiomyopathy. Cardiovascular Pathology, 2013, 22, 309-311.	0.7	5
160	Clinical applications of molecular genetic discoveries. Translational Research, 2016, 168, 6-14.	2.2	5
161	Molecular genetics of hypertrophic cardiomyopathy. Journal of Cardiac Failure, 1996, 2, S87-S95.	0.7	4
162	On Genetics of Dilated Cardiomyopathy and Transgenic Models. Circulation Research, 2001, 89, 3-5.	2.0	4

#	Article	IF	Citations
163	â€œInto Thin Airâ€•and the Genetics of Complex Traits. Circulation, 2002, 106, 768-769.	1.6	4
164	Recent advances in genetics and treatment of hypertrophic cardiomyopathy. Future Cardiology, 2005, 1, 341-353.	0.5	4
165	Clinical implications of the â€œpersonalâ€•genome. Current Atherosclerosis Reports, 2008, 10, 361-363.	2.0	4
166	A combinatorial oligogenic basis for the phenotypic plasticity between late-onset dilated and arrhythmogenic cardiomyopathy in a single family. , 2021, 1, .		4
167	Pharmacological suppression of the WNT signaling pathway attenuates age-dependent expression of the phenotype in a mouse model of arrhythmogenic cardiomyopathy. , 2021, 1, .		4
168	Cardiac Myosin Binding Protein-C Autoantibodies Are Potential Early Indicators of Cardiac Dysfunction andÂPatient Outcome in Acute CoronaryÂSyndrome. JACC Basic To Translational Science, 2017, 2, 122-131.	1.9	3
169	Update on hypertrophic cardiomyopathy. Texas Heart Institute Journal, 2010, 37, 322-3.	0.1	3
170	1.P.312 Homocyst(e)ine level but not MTHFR genotype predicts carotid atherosclerosis. Atherosclerosis, 1997, 134, 82-83.	0.4	2
171	Molecular Pathophysiology of Cardiomyopathies. , 2001, , 1045-1063.		2
172	Utilities and limitations of genetic testing for hypertropic cardiomyopathy. Expert Opinion on Medical Diagnostics, 2008, 2, 539-546.	1.6	2
173	DNA sequence variants and the practice of medicine. Current Opinion in Cardiology, 2010, 25, 182-185.	0.8	2
174	The Personal Genome And The Practice Of Cardiovascular Medicine. Methodist DeBakey Cardiovascular Journal, 2010, 6, 13-20.	0.5	2
175	Commentariesâ€”Another Addition to the Portfolio of Circulation Research. Circulation Research, 2011, 108, 157-157.	2.0	2
176	Molecular Analysis of Genotype/Phenotype Correlations of Hypertrophic Cardiomyopathy. Developments in Cardiovascular Medicine, 1995, , 3-19.	0.1	2
177	Statins and the Modulation of Cardiac Hypertrophy and Fibrosis: Implications in the Therapy of Heart Failure. , 2004, , 143-162.		1
178	Genome-wide association study of susceptibility alleles for coronary artery disease. Current Atherosclerosis Reports, 2008, 10, 183-185.	2.0	1
179	The genetic basis of cardiomyopathy. Current Cardiovascular Risk Reports, 2008, 2, 468-475.	0.8	1
180	Cardiovascular Genetics: Focus on Genetics of Coronary Artery Disease. Cardiovascular Medicine, 2015, , 727-735.	0.0	1

#	Article	IF	Citations
181	Role of the Extracellular Matrix inÂtheÂPathogenesis of HypertrophicÂCardiomyopathy. JACC Basic To Translational Science, 2019, 4, 506-508.	1.9	1
182	Genetic Testing in Cardiovascular Medicine. Texas Heart Institute Journal, 2018, 45, 231-232.	0.1	1
183	Oligogenic cardiomyopathy. , 2022, 2, .		1
184	Clinical significance of single nucleotide polymorphisms in PCSK9. Current Atherosclerosis Reports, 2007, 9, 175-6.	2.0	1
185	Molecular Genetic Basis of Cardiovascular Disease. Cardiology in Review, 1996, 4, 47-56.	0.6	0
186	Atrioventricular fibrous ring disruption promotes ventricular preexcitation in a mouse model of Wolff-Parkinson-white syndrome. Heart Rhythm, 2005, 2, S71.	0.3	0
187	MYH11 mutations result in a distinct vascular pathology driven by insulin-like growth factor1 and angiotensin II. Human Molecular Genetics, 2007, 17, 158-158.	1.4	0
188	Cardiac Hypertrophy. , 2007, , 1177-1188.		0
189	Genetic Testing For Hypertrophic Cardiomyopathy. Methodist DeBakey Cardiovascular Journal, 2008, 4, 17-20.	0.5	0
190	Heart Failure as a Consequence of Restrictive Cardiomyopathy. , 2011, , 395-407.		0
191	Errors in DNA replication and genetic diseases. Current Opinion in Cardiology, 2013, 28, 269-271.	0.8	0
192	Ali J. Marian. Circulation Research, 2014, 115, 549-551.	2.0	0
193	The Bottleneck in Genetic Testing. Circulation Research, 2015, 117, 586-588.	2.0	0
194	New landscape of cardiovascular genetics and genomics. Current Opinion in Cardiology, 2017, 32, 229-231.	0.8	0
195	To Seek the Holy Grail of Cardiac Progenitor Cells. Circulation Research, 2017, 121, 1208-1209.	2.0	0
196	Scientists on the Spot: A brief word with Ali J. Marian on cardiovascular genetics. Cardiovascular Research, 2018, 114, e91-e92.	1.8	0
197	Heart Failure as a Consequence of Hypertrophic Cardiomyopathy. , 2020, , 311-321.e6.		0
198	A tribute to James Thornton Willerson, M.D. November 16, 1939â€“September 16, 2020. Cardiovascular Research, 2020, 116, 2171-2172.	1.8	0

#	Article	IF	Citations
199	Editorial: Overcoming current limitations of genetic testing in cardiovascular medicine. Current Opinion in Cardiology, 2020, 35, 187-190.	0.8	0
200	Highlights of American Heart Association Scientific Sessions 2020: a virtual experience. Cardiovascular Research, 2021, 117, e10-e12.	1.8	0
201	Editorial: Cardiovascular complications of COVID-19. Current Opinion in Cardiology, 2021, 36, 253-255.	0.8	0
202	Pharmacogenetic study of statin therapy and cholesterol reduction. Current Atherosclerosis Reports, 2005, 7, 177-8.	2.0	0
203	Cholesteryl ester transfer protein TaqIB polymorphism in the cholesterol and recurrent events study. Current Atherosclerosis Reports, 2005, 7, 178-9.	2.0	0
204	Interleukin-18 and cardiovascular events. Current Atherosclerosis Reports, 2006, 8, 173-4.	2.0	0
205	Matrix metalloproteinase-I gene variants and risk of myocardial infarction. Current Atherosclerosis Reports, 2006, 8, 174-6.	2.0	0
206	A novel genetic risk factor for myocardial infarction. Current Atherosclerosis Reports, 2007, 9, 176-8.	2.0	0
207	Genetic basis of cardiovascular aging is at the core of human longevity. , 2022, 2, 25.		0